Parallel one-pot synthesis and structure–activity relationship study of symmetric formimidoester disulfides as a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors

The molecular duplication of non-nucleoside reverse transcriptase inhibitor (NNRTI) O-(2-phthalimidoethyl)– N-arylthiocarbamates (C-TCs) led to the identification of symmetric formimidoester disulfides (DSs) as a novel class of potent NNRTIs. The lead compound 1 [dimer of the isothiocarbamic form of...

Full description

Saved in:
Bibliographic Details
Published inBioorganic & medicinal chemistry Vol. 16; no. 12; pp. 6353 - 6363
Main Authors Cesarini, Sara, Spallarossa, Andrea, Ranise, Angelo, Schenone, Silvia, Bruno, Olga, La Colla, Paolo, Casula, Laura, Collu, Gabriella, Sanna, Giuseppina, Loddo, Roberta
Format Journal Article
LanguageEnglish
Published Oxford Elsevier Ltd 15.06.2008
Elsevier Science
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The molecular duplication of non-nucleoside reverse transcriptase inhibitor (NNRTI) O-(2-phthalimidoethyl)– N-arylthiocarbamates (C-TCs) led to the identification of symmetric formimidoester disulfides (DSs) as a novel class of potent NNRTIs. The lead compound 1 [dimer of the isothiocarbamic form of TC O-(2-phthalimidoethyl)– N-phenylthiocarbamate] turned out to prevent the wild-type HIV-1 multiplication in MT-4 cell culture with an EC 50 value of 0.35 μM. In order to perform a structure–activity relationship (SAR) study, we prepared 40 analogues of 1 by an unprecedented one-pot method of solution-phase parallel synthesis. The SAR strategy was focused on the variation of the N-aryl portion (mono-, di- and trisubstitution of the phenyl ring and its replacement with a 1-naphthyl, cyclopropyl or benzyl group) and of the 2-phthalimidoethyl moiety (introduction of a methyl on the phthalimide substructure, replacement of the phthalimide moiety with a phenyl ring and elongation of the ethyl linker). Most DSs proved to inhibit the wild-type HIV-1 replication in cell-based assays and 15 of them were active at nanomolar concentrations. The most potent congeners ( 11, 15, 16, 17, 18, 19, 20 and 32, EC 50: 10–70 nM) shared the N- para-substituted phenyl moiety. Compound 17 tested in enzyme assay against recombinant wild-type reverse transcriptase displayed an IC 50 value of 0.74 μM. Compounds 19 and 33 were active at micromolar concentrations against the clinically relevant Y181C and/or K103R resistant mutants.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0968-0896
1464-3391
DOI:10.1016/j.bmc.2008.05.010